Country for PR: United States
Contributor: PR Newswire New York
Thursday, November 03 2022 - 00:00
Turn Biotechnologies Names 25-year Biotech Industry Veteran Richard Peterson Chief Financial Officer
MOUNTAIN VIEW, Calif., Nov. 2, 2022 /PRNewswire-AsiaNet/ --

-- Seasoned Executive has Successful Track Record Working with Global Investors 
to Raise Billions of Dollars

Turn Biotechnologies, a cell rejuvenation company developing novel mRNA 
medicines to cure untreatable, age-related conditions, today announced it has 
appointed Richard "Ric" Peterson as chief financial officer.

Photo - 
Logo - 

Mr. Peterson, who has served as CFO of numerous public and private biotech and 
pharmaceutical companies, has deep experience with private financing, public 
offerings, and complex global transactions. He will oversee all financial 
functions and fundraising efforts as Turn Bio prepares to launch its clinical 

"Ric's background with biotech companies in various stages of development and 
his experience as a financial and business leader will be great assets as Turn 
Bio moves into the next phases of growth," said company CEO Anja Krammer. "As 
Turn Bio progresses toward the clinic, Ric will enhance our team's expertise 
and help communicate our unique vision for treating the diseases of aging 
within the investment community."

During his 25 years of serving as a chief financial officer, Peterson has led 
traditional fundraising efforts for pre-clinical, clinical and commercial 
companies, managed initial public offerings and overseen corporate purchases 
and sales. He has completed more than 40 transactions representing billions of 

"I am excited to join the team at Turn Bio at this important stage, when the 
company's potential for growth and value creation is exceptional," said 
Peterson. "The talented team of executives and cell rejuvenation pioneers has 
brought Turn Bio successfully to this point, achieved breakthroughs in 
epigenetic reprogramming and developed a game-changing delivery system that 
overcomes the leading obstacle to cell therapies.  I look forward to helping 
steer the next stage of our growth."

Peterson has worked with several clinical stage biopharmaceutical companies, 
including Clarus Therapeutics, Sienna Biopharmaceuticals, Dermavant Sciences 
Inc., and Novan Inc. He was also CFO of Medicis Pharmaceutical Corporation, a 
commercial pharmaceutical company. Under Peterson's guidance, Novan and Sienna 
completed successful IPOs. At Medicis, he helped lead the company's growth, 
which resulted in its acquisition for $2.6 billion by Valeant Pharmaceuticals 

Peterson serves as a director at Universal Insurance Holdings, where he chairs 
the Board's Audit Committee.


Turn Bio is a pre-clinical-stage company focused on repairing tissue at the 
cellular level and developing transformative drug delivery systems. The 
company's proprietary mRNA platform technology, ERA(TM), restores optimal gene 
expression by combatting the effects of aging in the epigenome. This restores 
cells' ability to prevent or treat disease and heal or regenerate tissue. It 
will help to fight incurable chronic diseases. Its eTurna(TM) Delivery Platform 
uses unique formulations to precisely deliver cargo to specific organs, 
tissues, and cell types.

The company is completing pre-clinical research on tailored therapies targeting 
indications in dermatology and immunology, and developing therapies for 
ophthalmology, osteo-arthritis, and the muscular system. For more information, 


Jim Martinez, rightstorygroup or (312) 543-9026

SOURCE: Turn Biotechnologies, Inc.